Sequential plasmapheresis and intravenous immunoglobulin therapy for refractory myasthenia gravis: Case report

Therapeutic Apheresis

Volumn 3, Issue 3, 1999, Pages 271-274

  Yeh, Jiann Horng ^a   Chiu, Hou Chang ^a  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Immunotherapy; Intravenous immunoglobulin; Myasthenia gravis; Plasma exchange; Plasmapheresis

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; DNA ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; PYRIDOSTIGMINE;

ADULT; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME;

ADULT; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYASTHENIA GRAVIS; PLASMAPHERESIS;

EID: 0032782556     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.1999.00150.x     Document Type: Article

References (11)

1. Kornfeld P, Fox S, Maier K, Mahjoub M. Ten years experiences with therapeutic plasmapheresis in a community hospital. J Clin Apheresis 1992;7:63-8.
2. Yeh JH, Chen WH, Lee MF, Shen HM, Chiu HC. Clinical experiences of double filtration plasmapheresis in the treatment of myasthenia gravis. Acta Neurol Sin 1995;4:107-12.
3. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment of plasmapheresis. Neurology 1996;47:840-3.
4. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C, for the Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997;41:789-96.
5. Imbach P, D'Ampuzzo V, Hirt A, Rossi E, Vest M, Barandun S, Baumgartner C, Morell A, Schoni M, Wagner HP. High-dose intravenous gammoglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-30.
6. Edan G, Landgraf F. Experiences with intravenous immunoglobulin in myasthenia gravis: A review. J Neurol Neurosurg Psychiatry 1994;57(Suppl.):55-6.
7. Bussel JB, Saal S, Gordon B. Combined plasma exchange and intravenous gammaglobulin in the treatment of patients with refractory immune thrombocytopenic purpura. Transfusion 1988;28:38-41.
8. Hauft WF, Rosenow F, van der Ven C, Borberg H, Pawlik G. Sequential treatment of Guillain Barré syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci 1996;137:145-9.
9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosis. Arthritis Rheum 1982;25:1271-7.
10. Besinger UA, Toyka KV, Homberg M, Heininger K, Hohfeld R, Fateh-Moghadam A. Myasthenia gravis: Long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983;33:1316-21.
11. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-30.